tofacitinib and Schnitzler-Syndrome

tofacitinib has been researched along with Schnitzler-Syndrome* in 1 studies

Other Studies

1 other study(ies) available for tofacitinib and Schnitzler-Syndrome

Article	Year
Case report: Successful treatment with tofacitinib and colchicine in a patient with Schnitzler syndrome. International journal of rheumatic diseases, 2023, Volume: 26, Issue:1 We report a case of late-onset Schnitzler syndrome successfully treated with Janus-activated kinase (JAK) inhibitors and colchicine. Schnitzler syndrome should be considered for recurrent chronic urticaria when accompanied by fever, fatigue, rapid weight loss, and poor response to antihistamine treatment. Skin biopsy, bone marrow biopsy, and electrophoresis help confirm the diagnosis. Early diagnosis and treatment can lead to complete resolution of symptoms. Besides interleukin (IL)-1 and IL-6 inhibitors, JAK inhibitors and colchicine may be considered as other choices of treatment. Topics: Colchicine; Humans; Interleukin-1; Piperidines; Schnitzler Syndrome; Urticaria	2023

Article

Year

Case report: Successful treatment with tofacitinib and colchicine in a patient with Schnitzler syndrome.

International journal of rheumatic diseases, 2023, Volume: 26, Issue:1

We report a case of late-onset Schnitzler syndrome successfully treated with Janus-activated kinase (JAK) inhibitors and colchicine. Schnitzler syndrome should be considered for recurrent chronic urticaria when accompanied by fever, fatigue, rapid weight loss, and poor response to antihistamine treatment. Skin biopsy, bone marrow biopsy, and electrophoresis help confirm the diagnosis. Early diagnosis and treatment can lead to complete resolution of symptoms. Besides interleukin (IL)-1 and IL-6 inhibitors, JAK inhibitors and colchicine may be considered as other choices of treatment.

Topics: Colchicine; Humans; Interleukin-1; Piperidines; Schnitzler Syndrome; Urticaria

2023